| abstract |
The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUC-1 or derivative thereof. The invention further provides pharmaceutical compositions comprising said constructs and proteins, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine, particularly in the treatment of MUC-1 expressing tumours. |